Filing Flows

Filing Flows › Innovate (VATE) › Q2 2026 › vs Q1 2026

Innovate (VATE) Q2 2026 vs Q1 2026 (quarter over quarter)

Innovate's revenue rose $56.8M (+16%) from $365M in Q1 2026 to $422M in Q2 2026. The biggest changes: Infrastructure +$56.1M (+16%); Life Sciences +$600K (+38%); Spectrum Segment +$100K (+2%). Gross margin 18.9% against 14.7% (+4.2 pts).

Innovate, Q2 2026: revenue $422M (+74% year over year), operating margin 8.2%, net earnings $10.7M, operating cash flow −$24.6M. The chart draws each line against Q1 2026, the increases inside each band.

Innovate: what changed, Q2 2026 vs Q1 2026Innovate: what changed, Q2 2026 vs Q1 2026Operating cash sources$97.0MWorking capital & other$97.0MCash used in operations$70.1MInfrastructure$56.1MPre-tax earnings$39.7MCost of revenue$30.8MNet earnings$27.5MGross profit$26.0MOperating profit$24.5MOther expense, net−$15.2M

Margins

Q2 2026Q1 2026Change
Gross margin18.9%14.7%+4.2 pts
Operating margin8.2%2.7%+5.4 pts
Net margin2.5%-4.6%+7.1 pts

Every line

LineQ2 2026Q1 2026Change%
Infrastructure$414M$358M$56.1M+16%
Spectrum Segment$5.4M$5.3M$100K+2%
Life Sciences$2.2M$1.6M$600K+38%
Revenue$422M$365M$56.8M+16%
Gross profit$79.5M$53.5M$26.0M+49%
Cost of revenue$342M$311M$30.8M+10%
Operating profit$34.5M$10.0M$24.5M+245%
Operating expenses$45.0M$43.5M$1.5M+3%
Pre-tax earnings$25.5M−$14.2M$39.7M—
Other expense, net$9.0M$24.2M−$15.2M-63%
SG&A$41.5M$39.4M$2.1M+5%
Other operating costs$3.5M$4.1M−$600K-15%
Net earnings$10.7M−$16.8M$27.5M—
Minority interests$1.7M−$300K$2.0M—
Income tax$13.1M$2.9M$10.2M+352%
Operating cash sources$42.7M−$54.3M$97.0M—
Depreciation & amortization$7.0M$7.4M−$400K-5%
Share-based compensation$400K$600K−$200K-33%
Cash used in operations$24.6M−$45.5M$70.1M—
Working capital & other$42.7M−$54.3M$97.0M—

Questions

How much did Innovate's revenue grow quarter over quarter in Q2 2026?

Innovate's revenue rose $56.8M (+16%) from $365M in Q1 2026 to $422M in Q2 2026.

What drove Innovate's revenue change in Q2 2026?

Infrastructure +$56.1M (+16%); Life Sciences +$600K (+38%); Spectrum Segment +$100K (+2%).

Q2 2026 results → · Compare in the interactive Sankey →